Oxcarbazepine NDC 68094-123

NDC codes

FDA NDC Directory

Product NDC (as listed)68094-123Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68094-0123Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68094-123-62	68094012362	3 TRAY in 1 CASE (68094-123-62) / 10 CUP, UNIT-DOSE in 1 TRAY / 5 mL in 1 CUP, UNIT-DOSE (68094-123-59)Marketed from Sep 13, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxcarbazepine
Generic name (nonproprietary): oxcarbazepine
Active ingredients: Oxcarbazepine — 300 mg/5mL
Dosage form: Suspension
Route: Oral
Labeler: Precision Dose, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202961
Marketing start: Sep 13, 2017
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 68094-123_43ea970d-701d-409d-b9a1-4e0c171ede4dSPL ID 43ea970d-701d-409d-b9a1-4e0c171ede4dSPL set ID 636fc847-b3d2-4255-a959-d75499fdb198RxCUI 283536UNII VZI5B1W380
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468094012362 followed by a unit qualifier and the quantity

Package 68094-0123-62. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 20, 2023.

Indications (excerpt from the label)

Oxcarbazepine oral suspension is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. Oxcarbazepine oral suspension is indicated for: Adults: Monotherapy or adjunctive therapy in the treatment of partial-onset seizures Pediatrics: - Monotherapy in the treatment of partial-onset seizures in children 4 to 16 years - Adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202961

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202961
Product	Strength	Form · route	Labeler	Product NDC
Oxcarbazepine	Oxcarbazepine 300 mg/5mL	SuspensionOral	Amneal Pharmaceuticals LLC	65162-649
Oxcarbazepine	Oxcarbazepine 300 mg/5mL	SuspensionOral	Bryant Ranch Prepack	72162-2088